As COVID-19 changes our world, it has never been more critical for leaders within our industry to share insights, key learnings and best practices to develop solutions that redefine possibilities for the patients we serve.
The J.P. Morgan Healthcare Conference, an annual event bringing together thousands of health leaders, innovators and members of the investment community, is a reminder of our industry’s incredible work throughout 2020 and provides a glimpse into the year ahead. As I attend this year’s virtual conference, I reflect on our accomplishments to-date and the ways we’ll continue to propel innovative solutions for our patients in 2021.
At Jazz, the past year was undoubtedly one of growth. Amid the anxiety and uncertainty, our employees around the world put our values into action through their hard work, dedication and persistence. This tenacity supported the continued evolution and diversification of our pipeline in both neuroscience and hematology-oncology, bringing solutions to patients who didn’t have one readily available to them. In total, we are on track to execute up to five key product launches from 2020 through 2021. As we leverage our momentum in these therapeutic areas, our focus will be to advance treatment outcomes for those we can most significantly impact.
Last year was also one for innovative collaboration at Jazz. When it comes to solving some of the greatest challenges and truly transforming the patient experience to improve outcomes, no one organization can do it alone. We know that by sourcing both internal and external innovation, we can better understand –and then, solve –patient challenges. One example is the research collaboration agreement we signed with Redx Pharma plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Collaborations like this one and others Jazz launched in the past year with the American Heart Association, the Myelodysplastic Syndromes (MDS) Foundation, Inc. and the Cancer Support Community all aim to improve the lives of patients in the communities we serve. In 2021, we will continue to collaborate with members of the healthcare community to better understand both patients’ needs and the external research that advances our core focus areas.
This year, our corporate strategy will remain focused on differentiating our assets to provide meaningful clinical benefits for patients. In the last five years, Jazz has more than quadrupled its R&D efforts in scale, investment and scope. As a result, we’re applying our expertise across our teams to accelerate and expand the development of next-generation therapies where there is an unmet need, such as idiopathic hypersomnia. This continued growth allows us to make substantial progress towards our goal of delivering nearly half of our 2022 revenues from products launched since 2019.
No matter how the world may shift, one constant will remain: our commitment to bringing meaningful treatments to those living with difficult, complex diseases. With continued innovation, and a commitment to invest in and leverage our pipeline and global platform, Jazz is well-positioned to change the lives of more patients, and we are excited about the future.
